Global Parry-Romberg Syndrome Market Size, Share, Forecast Report, 2020-2027

Parry-Romberg syndrome is also known as progressive hemifacial atrophy. It is a rare disease, which is characterized by the shrinking and degeneration of the tissues beneath the skin. The changes and deterioration spread slowly and it occurs on one side and rarely extends to other parts of the body. General symptoms, includes facial changes, which involves the tissues above the upper jaw or between the nose and the upper corner of the lip and subsequently progress to the mouth, areas around the eye, the ear, and the neck. Currently, no cure and treatments are available for the parry-Romberg syndrome.

Increasing prevalence of skin diseases, neurological abnormalities, and eye defects are the major driving factors for the growth of the market during the forecast period. Moreover, oral diseases also boost the market growth as the tissues of mouth, including the tongue, gingiva, teeth, and soft palate are commonly involved in Parry-Romberg syndrome.

According to the Centers for Disease Control And Prevention, skin diseases is the most common in the US and over 7% of skin related diseases that are tracked by skin cancer registries are adding fuel to the market growth.

According to the WHO, millions of people worldwide are affected by neurological abnormalities or disorder. More than 6 million people die because of stroke each year; over 80% of deaths take place in low and middle income countries, which will boost the market growth in developing regions.

On the other hand, high cost of current treatment methods, and long duration for complete cure, for instance, it takes one-two years for facial growth and after facial growth the surgery is proceeded, which may hamper the market growth.

The global Parry-Romberg syndrome market is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.
Segmentation
The global Parry-Romberg syndrome market is segmented on the basis of diagnosis, treatment, and end user.

On the basis of diagnosis, the market is segmented into physical examination, MRI, serum test, and other.

On the basis of treatment, the market is categorized into drug treatment, surgery, and others. The drug treatment is further segmented into methotrexate, corticosteroids, cyclophosphamide, azathioprine, and others. The surgery is sub-segmented into orthognathic surgery, microsurgical reconstructive surgery, and others.

On the basis of end user, the market is segmented into hospitals & clinics, physical therapists, and others.

Key Players
Some of the key players in this market are DePuy Synthes (U.S.), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), Abbott (US), Immediate Media Company Ltd. (US), Taj Pharmaceuticals Ltd., Pfizer, Inc., Sanofi-Aventis, Biogen, Inc., GlaxoSmithKline, Inc., and AstraZeneca plc.